mCRC Phase II 'CHIME' Trial - Merck Serono collaboration

HA-Irinotecan as part of the FOLFIRI regimen plus Erbitux (cetuximab) in Metastatic Colorectal Cancer

This new investigator sponsored Phase II trial is being conducted by Assoc. Prof. Peter Gibbs from the Walter and Eliza Hall Institute, and is supported jointly with Alchemia and Merck Serono.

Trial Objectives

To generate clinical safety and efficacy data for HA-Irinotecan as a component of the FOLFIRI regimen when used in conjuction with Erbitux (cetuximab), which is one of the most clincally relevant regiments used to treat metastatic colorectal cancer patients.

Duration: Two years
Number of Patients: 45
Primary Endpoint: Safety
Secondary Endpoint: Progression-free survival, time-to-progression, time-to-treatment failure, overall survival, disease control rate, objective respponse rate and duration of response